The “Eureka Moment”: Aspirin’s Unexpected Connection
The researchers then sought to identify a way to target ARHGEF1 and restore T-cell function. Through a process of elimination, they discovered that thromboxane A2 (TXA2), a clotting factor, activates ARHGEF1 when it exposes T-cells. TXA2 is already well-known for its role in blood clotting and its link to aspirin. TXA2 is produced by platelets, small cells in the blood that help form clots to stop bleeding.
Aspirin slows down the production of TXA2, reducing platelet aggregation and preventing blood clots. This is why aspirin is commonly used to prevent heart attacks and strokes, by thinning the blood. The researchers realized that aspirin‘s ability to inhibit TXA2 production could also have an impact on cancer metastasis. By reducing TXA2 levels, aspirin could prevent ARHGEF1 from being activated, thereby releasing T-cells from suppression and allowing them to attack cancer cells.
To test this hypothesis, the researchers conducted experiments in mice with melanoma, a type of skin cancer that is prone to metastasis. They found that mice treated with aspirin had a significantly lower frequency of metastases compared to control mice. TXA2’s release of T-cells from suppression caused this effect, confirming that the immune system mediates aspirin’s anti-metastatic activity.